Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00870987 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria
A Phase 1 study of Malaria, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
- 1
- Study location
NCT00870987: Completed Phase 1 study of Malaria, sponsored by U.S. Army Medical Research and Development Command.
NCT00870987 is a Phase 1 study of Malaria that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 82 participants, below the 255-participant average among 27 other Malaria trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00870987, a Phase 1 study of Malaria, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the safety and effectiveness of a new malaria vaccine, the DNA-Ad vaccine. The study is specifically looking at a vaccine regimen against Plasmodium falciparum, the most deadly form of malaria.
Primary Outcome
The vaccine will be considered safe and well-tolerated if there are no severe or serious adverse events (AE) related to vaccine administration or if any severe events are relatively benign (e.g. erythema meeting criteria for severe due to its dimensions but not significantly affecting the activities of daily living for the subject) or brief in duration (e.g. less than 48 hours). The AEs will be assessed according to the method below. 1. Occurrence, severity, and duration of any solicited sympt
Conditions Studied
Interventions
- BIOLOGICAL DNA vaccine prime
- BIOLOGICAL adenovirus type 5 vaccine boost
Study Locations (1)
Maryland
- Clinical Trials Center, WRAIR - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2009-05 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
What the finished NCT00870987 record still lists
NCT00870987 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 255-participant average among 27 other Malaria trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Malaria appearing as the primary indexed condition, and to 2 interventions - of which DNA vaccine prime is the first listed.
NCT00870987 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00870987 about?
NCT00870987 is a clinical study titled "Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria". The purpose of this study is to test the safety and effectiveness of a new malaria vaccine, the DNA-Ad vaccine. The study is specifically looking at a vaccine regimen against Plasmodium falciparum, the most deadly form of malaria.
What is the current status of trial NCT00870987?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2009-05. Estimated completion is 2015-07.
What conditions does trial NCT00870987 study?
This clinical trial studies the following conditions: Malaria.
What interventions are being tested in trial NCT00870987?
The interventions under investigation include: DNA vaccine prime (BIOLOGICAL), adenovirus type 5 vaccine boost (BIOLOGICAL).
Who is sponsoring clinical trial NCT00870987?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00870987 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00870987's enrollment target sits among peer trials
82 13th of 27 higher than 15 of 27 other Malaria trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malaria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Oral E1018 in Healthy Adult Participants
RECRUITING · Phase 1
-
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
RECRUITING · Phase 1
-
First-in-Human PfSPZ-LARC2 Vaccination/CHMI
ACTIVE NOT RECRUITING · Phase 1
-
A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
ACTIVE NOT RECRUITING · Phase 1
-
Trial to Evaluate CIS43LS in Healthy Adults
COMPLETED · Phase 1
-
Blood-Stage Plasmodium Vivax Cell Bank
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia